Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > My feeling

<< Previous

Bullboard Posts

Next >>

Comment by Marky1on Dec 28, 2020 1:12pm

237 Views

Post# 32187801

RE:RE:RE:My feeling

Excellent posts Pragmatist ang Mugs! Totally agree with what you fine people said

The BOD will be acting, I believe, in the best interest of the shareholders...They have a lot of skin in the game...Smart money is heavily invested here

The science is real...no subjectivity involved here...Pvalues were created to take the guess work out of the results
Patience will be rewarded!
2021 starts next week...Fortunes will be made here
by 2028 , I believe that the Nobel Prize will be awarded to Dr. John Wallace for his life's work with H2S drug technology!
Best of luck to everyone here ( longs )
Jean Marc

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario